CXCL9 and nasopharyngeal carcinoma: Although we did not observe any differences in CXCR3 ligands CXCL9, 10, 11 and 13, patients with no NPC recurrence had higher quantities of circulating CCL14 (ligands for CCR1 and CCR5) and CCL15 (ligand for CCR1) pre-RT when compared to patients who had NPC recurrence (Supplementary Figure S6).